Effect of low-dose heparin on fibrinogen levels in patients with chronic ischemic heart disease

D. Prisco, R. Paniccia, B. Bandinelli, A. M. Gori, M. Attanasio, B. Giusti, M. Comeglio, R. Abbate, G. F. Gensini, G. G. Neri Serneri

Research output: Contribution to journalArticle

Abstract

Several prospective studies have demonstrated that high plasma fibrinogen levels are associated with an increased risk of ischemic heart disease. Since in most patients an increased thrombin generation has been reported, we investigated whether the control of thrombin generation could affect plasma fibrinogen levels. Forty male outpatients (20 asymptomatic with previous myocardial infarction and 20 with stable effort angina) were enrolled in a randomized medium-term (6 months)cross-over study. Clottable fibrinogen, according to Clauss, prothrombin fragment 1+2, thrombin-antithrombin complex, and fibrinopeptide A were evaluated in relation to treatment with low-dose heparin. After a 15-day wash-out period, during which patients had been treated only with nitrates if needed, patients were allocated to two sequential periods of treatment with standard heparin (12,500 U, subcutaneously daily) plus antianginal treatment or antianginal treatment alone, separated by a second 15-day wash-out period. At the end of the treatment period with low-dose heparin significant decreases in the plasma fibrinogen (2.5 ± 0.6 g/1 vs. 3.3 ± 0.5 g/l, P

Original languageEnglish
Pages (from-to)170-173
Number of pages4
JournalInternational Journal of Clinical & Laboratory Research
Volume28
Issue number3
DOIs
Publication statusPublished - Sep 1998

Fingerprint

Fibrinogen
Myocardial Ischemia
Heparin
Plasmas
Thrombin
Fibrinopeptide A
Therapeutics
Stable Angina
Nitrates
Cross-Over Studies
Outpatients
Myocardial Infarction
Prospective Studies

Keywords

  • Fibrinogen
  • Fibrinopeptide A
  • Heparin
  • Prothrombin fragment 1+2
  • Thrombin-antithrombin complex

ASJC Scopus subject areas

  • Clinical Biochemistry

Cite this

Prisco, D., Paniccia, R., Bandinelli, B., Gori, A. M., Attanasio, M., Giusti, B., ... Neri Serneri, G. G. (1998). Effect of low-dose heparin on fibrinogen levels in patients with chronic ischemic heart disease. International Journal of Clinical & Laboratory Research, 28(3), 170-173. https://doi.org/10.1007/s005990050038

Effect of low-dose heparin on fibrinogen levels in patients with chronic ischemic heart disease. / Prisco, D.; Paniccia, R.; Bandinelli, B.; Gori, A. M.; Attanasio, M.; Giusti, B.; Comeglio, M.; Abbate, R.; Gensini, G. F.; Neri Serneri, G. G.

In: International Journal of Clinical & Laboratory Research, Vol. 28, No. 3, 09.1998, p. 170-173.

Research output: Contribution to journalArticle

Prisco, D, Paniccia, R, Bandinelli, B, Gori, AM, Attanasio, M, Giusti, B, Comeglio, M, Abbate, R, Gensini, GF & Neri Serneri, GG 1998, 'Effect of low-dose heparin on fibrinogen levels in patients with chronic ischemic heart disease', International Journal of Clinical & Laboratory Research, vol. 28, no. 3, pp. 170-173. https://doi.org/10.1007/s005990050038
Prisco, D. ; Paniccia, R. ; Bandinelli, B. ; Gori, A. M. ; Attanasio, M. ; Giusti, B. ; Comeglio, M. ; Abbate, R. ; Gensini, G. F. ; Neri Serneri, G. G. / Effect of low-dose heparin on fibrinogen levels in patients with chronic ischemic heart disease. In: International Journal of Clinical & Laboratory Research. 1998 ; Vol. 28, No. 3. pp. 170-173.
@article{2479fdda51ae4d4eb295392e1bb4b37a,
title = "Effect of low-dose heparin on fibrinogen levels in patients with chronic ischemic heart disease",
abstract = "Several prospective studies have demonstrated that high plasma fibrinogen levels are associated with an increased risk of ischemic heart disease. Since in most patients an increased thrombin generation has been reported, we investigated whether the control of thrombin generation could affect plasma fibrinogen levels. Forty male outpatients (20 asymptomatic with previous myocardial infarction and 20 with stable effort angina) were enrolled in a randomized medium-term (6 months)cross-over study. Clottable fibrinogen, according to Clauss, prothrombin fragment 1+2, thrombin-antithrombin complex, and fibrinopeptide A were evaluated in relation to treatment with low-dose heparin. After a 15-day wash-out period, during which patients had been treated only with nitrates if needed, patients were allocated to two sequential periods of treatment with standard heparin (12,500 U, subcutaneously daily) plus antianginal treatment or antianginal treatment alone, separated by a second 15-day wash-out period. At the end of the treatment period with low-dose heparin significant decreases in the plasma fibrinogen (2.5 ± 0.6 g/1 vs. 3.3 ± 0.5 g/l, P",
keywords = "Fibrinogen, Fibrinopeptide A, Heparin, Prothrombin fragment 1+2, Thrombin-antithrombin complex",
author = "D. Prisco and R. Paniccia and B. Bandinelli and Gori, {A. M.} and M. Attanasio and B. Giusti and M. Comeglio and R. Abbate and Gensini, {G. F.} and {Neri Serneri}, {G. G.}",
year = "1998",
month = "9",
doi = "10.1007/s005990050038",
language = "English",
volume = "28",
pages = "170--173",
journal = "Ricerca in Clinica e in Laboratorio",
issn = "0940-5437",
publisher = "Springer Verlag",
number = "3",

}

TY - JOUR

T1 - Effect of low-dose heparin on fibrinogen levels in patients with chronic ischemic heart disease

AU - Prisco, D.

AU - Paniccia, R.

AU - Bandinelli, B.

AU - Gori, A. M.

AU - Attanasio, M.

AU - Giusti, B.

AU - Comeglio, M.

AU - Abbate, R.

AU - Gensini, G. F.

AU - Neri Serneri, G. G.

PY - 1998/9

Y1 - 1998/9

N2 - Several prospective studies have demonstrated that high plasma fibrinogen levels are associated with an increased risk of ischemic heart disease. Since in most patients an increased thrombin generation has been reported, we investigated whether the control of thrombin generation could affect plasma fibrinogen levels. Forty male outpatients (20 asymptomatic with previous myocardial infarction and 20 with stable effort angina) were enrolled in a randomized medium-term (6 months)cross-over study. Clottable fibrinogen, according to Clauss, prothrombin fragment 1+2, thrombin-antithrombin complex, and fibrinopeptide A were evaluated in relation to treatment with low-dose heparin. After a 15-day wash-out period, during which patients had been treated only with nitrates if needed, patients were allocated to two sequential periods of treatment with standard heparin (12,500 U, subcutaneously daily) plus antianginal treatment or antianginal treatment alone, separated by a second 15-day wash-out period. At the end of the treatment period with low-dose heparin significant decreases in the plasma fibrinogen (2.5 ± 0.6 g/1 vs. 3.3 ± 0.5 g/l, P

AB - Several prospective studies have demonstrated that high plasma fibrinogen levels are associated with an increased risk of ischemic heart disease. Since in most patients an increased thrombin generation has been reported, we investigated whether the control of thrombin generation could affect plasma fibrinogen levels. Forty male outpatients (20 asymptomatic with previous myocardial infarction and 20 with stable effort angina) were enrolled in a randomized medium-term (6 months)cross-over study. Clottable fibrinogen, according to Clauss, prothrombin fragment 1+2, thrombin-antithrombin complex, and fibrinopeptide A were evaluated in relation to treatment with low-dose heparin. After a 15-day wash-out period, during which patients had been treated only with nitrates if needed, patients were allocated to two sequential periods of treatment with standard heparin (12,500 U, subcutaneously daily) plus antianginal treatment or antianginal treatment alone, separated by a second 15-day wash-out period. At the end of the treatment period with low-dose heparin significant decreases in the plasma fibrinogen (2.5 ± 0.6 g/1 vs. 3.3 ± 0.5 g/l, P

KW - Fibrinogen

KW - Fibrinopeptide A

KW - Heparin

KW - Prothrombin fragment 1+2

KW - Thrombin-antithrombin complex

UR - http://www.scopus.com/inward/record.url?scp=7344230533&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=7344230533&partnerID=8YFLogxK

U2 - 10.1007/s005990050038

DO - 10.1007/s005990050038

M3 - Article

C2 - 9801927

AN - SCOPUS:7344230533

VL - 28

SP - 170

EP - 173

JO - Ricerca in Clinica e in Laboratorio

JF - Ricerca in Clinica e in Laboratorio

SN - 0940-5437

IS - 3

ER -